NCT04741074 - Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 23, 2021

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2023

Conditions

CKDDiabetic Kidney DiseaseType 2 Diabetes Mellitus in ObeseObesitySevere Obesity

Interventions

DRUG

Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution

Dose will be started at 0.25 mg per week. Dose escalation will occur every 4 weeks to mitigate risk of gastrointestinal side effects to a maximum dose of 1.0 mg per week.

DRUG

Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution

Matched placebo solution for injection will be provided by Novo Nordisk in a 1.5 ml pre-filled pen-injector for subcutaneous injection with the same instructions on dose escalation.

Trial Locations (2)

17821

Geisinger Medical Center, Danville

18702

Geisinger Wyoming Valley, Wilkes-Barre